Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis

Abstract Background Previous studies showed that type 2 short bowel syndrome (SBS) rats were accompanied by severe intestinal bacterial dysbiosis. Limited data are available for intestinal fungal dysbiosis. Moreover, no effective therapeutic drugs are available for these microbiota dysbiosis. The ai...

Full description

Bibliographic Details
Main Authors: Xiuting Hu, Wei Cheng, Shengxian Fan, Yuhua Huang, Xi Chen, Zhiwei Jiang, Jian Wang
Format: Article
Language:English
Published: BMC 2021-06-01
Series:BMC Infectious Diseases
Subjects:
Online Access:https://doi.org/10.1186/s12879-021-06270-w
id doaj-b5f7569698a94b3b812d7c20c30b2462
record_format Article
spelling doaj-b5f7569698a94b3b812d7c20c30b24622021-06-20T11:07:57ZengBMCBMC Infectious Diseases1471-23342021-06-0121111710.1186/s12879-021-06270-wTherapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosisXiuting Hu0Wei Cheng1Shengxian Fan2Yuhua Huang3Xi Chen4Zhiwei Jiang5Jian Wang6State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing UniversityDepartment of General Surgery, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese MedicineDepartment of General Surgery, Nanjing Drum Tower Hospital, Medical School of Nanjing UniversityDepartment of General Surgery, Jinling Hospital, Medical School of Nanjing UniversityState Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing UniversityDepartment of General Surgery, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese MedicineDepartment of General Surgery, Nanjing Drum Tower Hospital, Medical School of Nanjing UniversityAbstract Background Previous studies showed that type 2 short bowel syndrome (SBS) rats were accompanied by severe intestinal bacterial dysbiosis. Limited data are available for intestinal fungal dysbiosis. Moreover, no effective therapeutic drugs are available for these microbiota dysbiosis. The aims of our study were to investigate the therapeutic potential of glucagon-like peptide 2 (GLP-2) for these microbiota dysbiosis in type 2 SBS rats. Methods 8-week-old male SD rats which underwent 80% small bowel resection, ileocecum resection, partial colon resection and jejunocolostomy, were treated with saline (SBS group, n = 5) or GLP-2 (GLP2.SBS group, n = 5). The Sham group rats which underwent transection and re-anastomosis were given a saline placebo (Sham group, n = 5). 16S rRNA and ITS sequencing were applied to evaluate the colonic bacterial and fungal composition at 22 days after surgery, respectively. Results The relative abundance of Actinobacteria, Firmicutes and proinflammatory Proteobacteria increased significantly in SBS group rats, while the relative abundance of Bacteroidetes, Verrucomicrobia and Tenericutes decreased remarkably. GLP-2 treatment significantly decreased Proteus and increased Clostridium relative to the saline treated SBS rats. The diversity of intestinal fungi was significantly increased in SBS rats, accompanied with some fungi abnormally increased and some resident fungi (e.g., Penicillium) significantly decreased. GLP-2 treatment significantly decreased Debaryomyces and Meyerozyma, and increased Penicillium. Moreover, GLP-2 partially restored the bacteria-fungi interkingdom interaction network of SBS rats. Conclusion Our study confirms the bacterial and fungal dysbiosis in type 2 SBS rats, and GLP-2 partially ameliorated these microbiota dysbiosis.https://doi.org/10.1186/s12879-021-06270-wIntestinal bacterial and fungalDysbiosisShort bowel syndromeIntestinotrophic hormoneGlucagon-like peptide 2
collection DOAJ
language English
format Article
sources DOAJ
author Xiuting Hu
Wei Cheng
Shengxian Fan
Yuhua Huang
Xi Chen
Zhiwei Jiang
Jian Wang
spellingShingle Xiuting Hu
Wei Cheng
Shengxian Fan
Yuhua Huang
Xi Chen
Zhiwei Jiang
Jian Wang
Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis
BMC Infectious Diseases
Intestinal bacterial and fungal
Dysbiosis
Short bowel syndrome
Intestinotrophic hormone
Glucagon-like peptide 2
author_facet Xiuting Hu
Wei Cheng
Shengxian Fan
Yuhua Huang
Xi Chen
Zhiwei Jiang
Jian Wang
author_sort Xiuting Hu
title Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis
title_short Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis
title_full Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis
title_fullStr Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis
title_full_unstemmed Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis
title_sort therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis
publisher BMC
series BMC Infectious Diseases
issn 1471-2334
publishDate 2021-06-01
description Abstract Background Previous studies showed that type 2 short bowel syndrome (SBS) rats were accompanied by severe intestinal bacterial dysbiosis. Limited data are available for intestinal fungal dysbiosis. Moreover, no effective therapeutic drugs are available for these microbiota dysbiosis. The aims of our study were to investigate the therapeutic potential of glucagon-like peptide 2 (GLP-2) for these microbiota dysbiosis in type 2 SBS rats. Methods 8-week-old male SD rats which underwent 80% small bowel resection, ileocecum resection, partial colon resection and jejunocolostomy, were treated with saline (SBS group, n = 5) or GLP-2 (GLP2.SBS group, n = 5). The Sham group rats which underwent transection and re-anastomosis were given a saline placebo (Sham group, n = 5). 16S rRNA and ITS sequencing were applied to evaluate the colonic bacterial and fungal composition at 22 days after surgery, respectively. Results The relative abundance of Actinobacteria, Firmicutes and proinflammatory Proteobacteria increased significantly in SBS group rats, while the relative abundance of Bacteroidetes, Verrucomicrobia and Tenericutes decreased remarkably. GLP-2 treatment significantly decreased Proteus and increased Clostridium relative to the saline treated SBS rats. The diversity of intestinal fungi was significantly increased in SBS rats, accompanied with some fungi abnormally increased and some resident fungi (e.g., Penicillium) significantly decreased. GLP-2 treatment significantly decreased Debaryomyces and Meyerozyma, and increased Penicillium. Moreover, GLP-2 partially restored the bacteria-fungi interkingdom interaction network of SBS rats. Conclusion Our study confirms the bacterial and fungal dysbiosis in type 2 SBS rats, and GLP-2 partially ameliorated these microbiota dysbiosis.
topic Intestinal bacterial and fungal
Dysbiosis
Short bowel syndrome
Intestinotrophic hormone
Glucagon-like peptide 2
url https://doi.org/10.1186/s12879-021-06270-w
work_keys_str_mv AT xiutinghu therapeuticpotentialofanintestinotrophichormoneglucagonlikepeptide2fortreatmentoftype2shortbowelsyndromeratswithintestinalbacterialandfungaldysbiosis
AT weicheng therapeuticpotentialofanintestinotrophichormoneglucagonlikepeptide2fortreatmentoftype2shortbowelsyndromeratswithintestinalbacterialandfungaldysbiosis
AT shengxianfan therapeuticpotentialofanintestinotrophichormoneglucagonlikepeptide2fortreatmentoftype2shortbowelsyndromeratswithintestinalbacterialandfungaldysbiosis
AT yuhuahuang therapeuticpotentialofanintestinotrophichormoneglucagonlikepeptide2fortreatmentoftype2shortbowelsyndromeratswithintestinalbacterialandfungaldysbiosis
AT xichen therapeuticpotentialofanintestinotrophichormoneglucagonlikepeptide2fortreatmentoftype2shortbowelsyndromeratswithintestinalbacterialandfungaldysbiosis
AT zhiweijiang therapeuticpotentialofanintestinotrophichormoneglucagonlikepeptide2fortreatmentoftype2shortbowelsyndromeratswithintestinalbacterialandfungaldysbiosis
AT jianwang therapeuticpotentialofanintestinotrophichormoneglucagonlikepeptide2fortreatmentoftype2shortbowelsyndromeratswithintestinalbacterialandfungaldysbiosis
_version_ 1721370484230062080